Abstract
Two patients with primary hypothyroidism who developed neuroleptic malignant syndrome (NMS) are described. Thyroid disease might predispose to NMS by altering brain dopamine metabolism.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Caroff S. N. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980 Mar;41(3):79–83. [PubMed] [Google Scholar]
- Foord S. M., Peters J. R., Dieguez C., Shewring G., Hall R., Scanlon M. F. Thyrotropin regulates thyrotroph responsiveness to dopamine in vitro. Endocrinology. 1986 Apr;118(4):1319–1326. doi: 10.1210/endo-118-4-1319. [DOI] [PubMed] [Google Scholar]
- Funatsu K. S., Inanaga K. Modulation of dopamine receptors by thyrotropin-releasing hormone in the rat brain. Peptides. 1987 Mar-Apr;8(2):319–325. doi: 10.1016/0196-9781(87)90107-0. [DOI] [PubMed] [Google Scholar]
- Guzé B. H., Baxter L. R., Jr Current concepts. Neuroleptic malignant syndrome. N Engl J Med. 1985 Jul 18;313(3):163–166. doi: 10.1056/NEJM198507183130306. [DOI] [PubMed] [Google Scholar]
- Lim R. Idiopathic hypoparathyroidism presenting as the neuroleptic malignant syndrome. Br J Hosp Med. 1989 Feb;41(2):182–182. [PubMed] [Google Scholar]
- Reymond M. J., Benotto W., Lemarchand-Béraud T. The secretory activity of the tuberoinfundibular dopaminergic neurons is modulated by the thyroid status in the adult rat: consequence on prolactin secretion. Neuroendocrinology. 1987 Jun;46(1):62–68. doi: 10.1159/000124797. [DOI] [PubMed] [Google Scholar]